EGFR and breast neoplasm: Furthermore, the intratumoral treatment of doxorubicin at a low dose (2.5 mg/kg of body weight) along with either the potent EGFR inhibitor/compound 1e or standard EGFR inhibitor, PD153035 in mice xenotransplanted with CD24−/CD44+‐breast CSCs significantly decreased the tumor size as compared with a low dose of doxorubicin alone that was comparable to the high dose of doxorubicin treated group suggesting the enhanced therapeutic potential of EGFR inhibitor in reducing doxorubicin‐mediated breast tumor growth.